Patents by Inventor Masunori Kajikawa
Masunori Kajikawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230011171Abstract: A sample for evaluating performance of a genetic testing apparatus includes, a nucleic acid A; and a nucleic acid B, in which the nucleic acid A and the nucleic acid B have mutually different sequences. The nucleic acid A contains a specific number of molecules, and the nucleic acid B contains a number of molecules higher than the number of molecules of the nucleic acid A. A ratio A/B of the number of molecules of the nucleic acid A with respect to the number of molecules of the nucleic acid B is specified.Type: ApplicationFiled: June 30, 2022Publication date: January 12, 2023Applicant: Ricoh Company, Ltd.Inventors: Yusuke OSAKI, Satoshi Nakazawa, Yuuki Yonekawa, Hirotaka Unno, Michie Hashimoto, Masunori Kajikawa
-
Patent number: 10730937Abstract: An anti-HMGB1 antibody comprising a light chain variable region comprising complementarity-determining regions or the like including amino acid sequences of SEQ ID NOs: 4 to 6, and a heavy chain variable region comprising complementarity-determining regions or the like including amino acid sequences of SEQ ID NOs: 10 to 12, or an anti-HMGB1 antibody comprising a light chain variable region or the like comprising an amino acid sequence of SEQ ID NO: 3, and a heavy chain variable region comprising an amino acid sequence or the like of SEQ ID NO: 9, and a composition for treating or preventing Alzheimer's disease, comprising the same as an active ingredient.Type: GrantFiled: August 8, 2017Date of Patent: August 4, 2020Assignee: National University Corporation Tokyo Medical and Dental UniversityInventors: Hitoshi Okazawa, Masunori Kajikawa
-
Publication number: 20190211092Abstract: An anti-HMGB1 antibody comprising a light chain variable region comprising complementarity-determining regions or the like including amino acid sequences of SEQ ID NOs: 4 to 6, and a heavy chain variable region comprising complementarity-determining regions or the like including amino acid sequences of SEQ ID NOs: 10 to 12, or an anti-HMGB1 antibody comprising a light chain variable region or the like comprising an amino acid sequence of SEQ ID NO: 3, and a heavy chain variable region comprising an amino acid sequence or the like of SEQ ID NO: 9, and a composition for treating or preventing Alzheimer's disease, comprising the same as an active ingredient.Type: ApplicationFiled: August 8, 2017Publication date: July 11, 2019Applicant: National University Corporation Tokyo Medical and Dental UniversityInventors: Hitoshi OKAZAWA, Masunori KAJIKAWA
-
Patent number: 9416189Abstract: An object is to find a target molecule effective for cancer treatments and the like and to provide an antibody capable of specifically binding to the molecule, an anticancer agent comprising the antibody as an active ingredient, and so forth. Hence, prostate cancer cell lines (LNCaP-CR cells and LNCaP cells) were compared by SST-REX, and CXADR was identified as a molecule involved in tumor formation and so on. Then, a monoclonal antibody against CXADR was prepared, and the anti-cancer activity, ADCC activity, CDC activity, and so forth were examined. The result revealed that an antibody capable of binding to an epitope present at positions 181 to 230 of a CXADR protein derived from human exhibited an anti-cancer activity against prostate cancer cells, pancreatic cancer cells, and colorectal cancer cells. Further, it was also revealed that the antibody had an ADCC activity and a CDC activity. Moreover, the structures of light chain and heavy chain variable regions of the antibody were successfully determined.Type: GrantFiled: May 13, 2013Date of Patent: August 16, 2016Assignees: MICROBIAL CHEMISTRY RESEARCH FOUNDATION, MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.Inventors: Manabu Kawada, Hiroyuki Inoue, Shuichi Sakamoto, Masunori Kajikawa, Masahito Sugiura, Sakiko Urano
-
Publication number: 20150140018Abstract: An object is to find a target molecule effective for cancer treatments and the like and to provide an antibody capable of specifically binding to the molecule, an anticancer agent comprising the antibody as an active ingredient, and so forth. Hence, prostate cancer cell lines (LNCaP-CR cells and LNCaP cells) were compared by SST-REX, and CXADR was identified as a molecule involved in tumor formation and so on. Then, a monoclonal antibody against CXADR was prepared, and the anti-cancer activity, ADCC activity, CDC activity, and so forth were examined. The result revealed that an antibody capable of binding to an epitope present at positions 181 to 230 of a CXADR protein derived from human exhibited an anti-cancer activity against prostate cancer cells, pancreatic cancer cells, and colorectal cancer cells. Further, it was also revealed that the antibody had an ADCC activity and a CDC activity. Moreover, the structures of light chain and heavy chain variable regions of the antibody were successfully determined.Type: ApplicationFiled: May 13, 2013Publication date: May 21, 2015Applicants: MEDICAL & BIOLOGICAL LABORATORIES CO., LTD., MICROBIAL CHEMISTRY RESEARCH FOUNDATIONInventors: Manabu Kawada, Hiroyuki Inoue, Shuichi Sakamoto, Masunori Kajikawa, Masahito Sugiura, Sakiko Urano
-
Publication number: 20150037886Abstract: The present invention provides an agent for the prophylaxis or therapy of autoimmune diseases or allergic diseases, which contains an anti-Embigin antibody, particularly an anti-Embigin antibody showing cytotoxicity or a cytotoxicity inducing activity, an agent for the prophylaxis or therapy of diseases involving Th17 cell, and a cytotoxic agent to Th17 cell. In addition, an agent for detection of Th17 cell, which contains an anti-Embigin antibody, a convenient detection method of Th17 cell, which uses the agent, a method of efficiently delivering a drug and the like in a Th17 cell selective manner, which uses an anti-Embigin antibody, and a drug delivery system to Th17 cell are provided.Type: ApplicationFiled: September 11, 2014Publication date: February 5, 2015Inventors: Koichi KINO, Toshihiro KAI, Mitsuhiro MATSUMOTO, Masunori KAJIKAWA, Masahito SUGIURA, Emi SHIMIZU
-
Patent number: 8858944Abstract: The present invention provides an agent for the prophylaxis or therapy of autoimmune diseases or allergic diseases, which contains an anti-Embigin antibody, particularly an anti-Embigin antibody showing cytotoxicity or a cytotoxicity inducing activity, an agent for the prophylaxis or therapy of diseases involving Th17 cell, and a cytotoxic agent to Th17 cell. In addition, an agent for detection of Th17 cell, which contains an anti-Embigin antibody, a convenient detection method of Th17 cell, which uses the agent, a method of efficiently delivering a drug and the like in a Th17 cell selective manner, which uses an anti-Embigin antibody, and a drug delivery system to Th17 cell are provided.Type: GrantFiled: June 2, 2011Date of Patent: October 14, 2014Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Koichi Kino, Toshihiro Kai, Mitsuhiro Matsumoto, Masunori Kajikawa, Masahito Sugiura, Emi Shimizu
-
Patent number: 8828387Abstract: By utilizing an SST-REX method, a cDNA encoding a protein expressed on a cell surface or secreted from the cell was selected from a cDNA library derived from a cancer cell line. Monoclonal antibodies against the protein encoding the selected cDNA were prepared. The in vitro and in vivo anti-cancer activities and binding to various cancer cells lines were examined. As a result, a monoclonal antibody which binds to a PODXL2 protein, and which had excellent anti-cancer activities was found. Further, a region including an epitope of the antibody was successfully identified, and the amino acid sequences of variable regions of a light chain and a heavy chain were successfully determined.Type: GrantFiled: July 7, 2010Date of Patent: September 9, 2014Assignee: Actgen IncInventors: Masunori Kajikawa, Masahito Sugiura, Kazuyuki Atarashi, Emi Shimizu, Chiemi Matsumi, Yukie Saitoh
-
Publication number: 20140242085Abstract: As a result of the analysis by an SST-REX method so as to identify a target molecule for treating and testing an Aspergillus fumigatus infection, a YMAF1 protein has been found out, which is mainly localized in the cell wall of Aspergillus fumigatus. Moreover, it has been found out that YMAF1 protein-deficient Aspergillus fumigatus has reduced spore-forming ability and pathogenicity. Further, it has been found out that the survival rate of experimental mice having aspergillosis (invasive Aspergillus model mice) is improved by preparing and administering an antibody against the YMAF1 protein. Furthermore, it has been found out that Aspergillus fumigatus can be detected with a favorable sensitivity by an ELISA system using the antibody.Type: ApplicationFiled: August 12, 2011Publication date: August 28, 2014Applicants: MEDICAL & BIOLOGICAL LABORATORIES CO., LTD., NATIONAL INSTITUTE OF INFECTIOUS DISEASESInventors: Yoshitsugu Miyazaki, Satoshi Yamagoe, Masunori Kajikawa, Masahito Sugiura, Reiko Itoh, Hirotaka Kumagai
-
Publication number: 20130121914Abstract: The present invention provides an agent for the prophylaxis or therapy of autoimmune diseases or allergic diseases, which contains an anti-Embigin antibody, particularly an anti-Embigin antibody showing cytotoxicity or a cytotoxicity inducing activity, an agent for the prophylaxis or therapy of diseases involving Th17 cell, and a cytotoxic agent to Th17 cell. In addition, an agent for detection of Th17 cell, which contains an anti-Embigin antibody, a convenient detection method of Th17 cell, which uses the agent, a method of efficiently delivering a drug and the like in a Th17 cell selective manner, which uses an anti-Embigin antibody, and a drug delivery system to Th17 cell are provided.Type: ApplicationFiled: June 2, 2011Publication date: May 16, 2013Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.Inventors: Koichi Kino, Toshihiro Kai, Mitsuhiro Matsumoto, Masunori Kajikawa, Masahito Sugiura, Emi Shimizu
-
Publication number: 20120107364Abstract: By utilizing an SST-REX method, a cDNA encoding a protein expressed on a cell surface or secreted from the cell was selected from a cDNA library derived from a cancer cell line. Monoclonal antibodies against the protein encoding the selected cDNA were prepared. The in vitro and in vivo anti-cancer activities and binding to various cancer cells lines were examined. As a result, a monoclonal antibody which binds to a PODXL2 protein, and which had excellent anti-cancer activities was found. Further, a region including an epitope of the antibody was successfully identified, and the amino acid sequences of variable regions of a light chain and a heavy chain were successfully determined.Type: ApplicationFiled: July 7, 2010Publication date: May 3, 2012Applicant: ACTGEN INC.Inventors: Masunori Kajikawa, Masahito Sugiura, Kazuyuki Atarashi, Emi Shimizu, Chiemi Matsumi, Yukie Saitoh